Convergence of TGFβ and BMP signaling in regulating human bone marrow stromal cell differentiation

Mona Elsafadi¹, Tasneem Shinwari¹, Sami Al-Malki², Muthurangan Manikandan¹, Amer Mahmood³, Abdullah Aldahmash¹, Musaad Alfayez¹, Moustapha Kassem¹,⁴ & Nehad M. Alajez⁵,⁶

Targeting regulatory signaling pathways that control human bone marrow stromal (skeletal or mesenchymal) stem cell (hBMSC) differentiation and lineage fate determination is gaining momentum in the regenerative medicine field. Therefore, to identify the central regulatory mechanism of osteoblast differentiation of hBMSCs, the molecular phenotypes of two clonal hBMSC lines exhibiting opposite in vivo phenotypes, namely, bone forming (hBMSC⁺Bone) and non-bone forming (hBMSC⁻Bone) cells, were studied. Global transcriptome analysis revealed significant downregulation of several TGFβ-responsive genes, namely, TAGLN, TMP1, ACTA2, TGFβ2, SMAD6, SMAD9, BMP2, and BMP4 in hBMSC⁻Bone cells and upregulation on SERPINB2 and NOG. Transcriptomic data was associated with marked reduction in SMAD2 protein phosphorylation, which thereby implies the inactivation of TGFβ and BMP signaling in those cells. Concordantly, activation of TGFβ signaling in hBMSC⁻Bone cells using either recombinant TGFβ1 protein or knockdown of SERPINB2 TGFβ-responsive gene partially restored their osteoblastic differentiation potential. Similarly, the activation of BMP signaling using exogenous BMP4 or via siRNA-mediated knockdown of NOG partially restored the differentiation phenotype of hBMSC⁻Bone cells. Concordantly, recombinant NoG impaired ex vivo osteoblastic differentiation of hBMSC⁺Bone cells, which was associated with SERPINB2 upregulation. Our data suggests the existence of reciprocal relationship between TGFβ and BMP signaling that regulates hBMSC lineage commitment and differentiation, whilst provide a plausible strategy for generating osteoblastic committed cells from hBMSCs for clinical applications.

Human bone marrow-derived stromal (skeletal or mesenchymal) stem cells (hBMSC) exhibit the potential to differentiate into various mesodermal cells including osteoblasts, adipocytes, and chondrocytes¹. These have all been employed in regenerative medicine protocols for treating skeletal diseases e.g. non-healed fractures and the repair of bone defects⁵. However, cultured hBMSC cells exhibit functional and molecular heterogeneity with respect to differentiation capacity and bone formation potential³,⁴. This may explain the variability in the results obtained from hBMSC-based therapies⁵. One possible approach to enhance the therapeutic efficacy of hBMSC in bone regeneration protocols is to employ osteoblast-committed progenitors. Moreover, in certain disease conditions such as osteoporosis, for example, the impairment of osteoblast differentiation of hBMSC occurs, thereby necessitating the in vivo enhancement of the bone forming capacity of hBMSC⁶. However, this requires the identification of the signaling pathways and molecules that regulate hBMSC commitment into the osteoblastic lineage⁷,⁸.

We have previously employed global transcriptomics and proteomic approaches in order to identify the molecules and signaling pathways regulating hBMSC lineage specific differentiation based on studying the in vitro differentiation dynamics of hBMSC⁹-¹¹. Several follow up studies led to the identification of factors that are relevant for in vitro osteoblast differentiation and in vivo bone formation¹²,¹³. Whilst this approach is both useful

¹Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Saudi Arabia. ²College of Agriculture, King Saud University, Riyadh, Saudi Arabia. ³Prince Naif Health Research Center, King Saud University, Riyadh, 11461, Saudi Arabia. ⁴KMEB, Department of Endocrinology, University Hospital of Odense and University of Southern Denmark, Odense, Denmark. ⁵Cancer Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University (HBKU), Qatar Foundation, PO Box 34110, Doha, Qatar. ⁶College of health & life sciences, Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar. Correspondence and requests for materials should be addressed to N.M.A. (email: nalajez@hbku.edu.qa)
and hypothesis-generating, it requires extensive and time-consuming screening. In the current study, we performed reverse molecular phenotyping which is currently used in precision medicine. In this approach, the in vivo phenotype is interrogated based on molecular phenotyping in order to identify the signaling pathways which are to be targeted in individualized therapy. Using a similar approach, we tested the possibility of identifying those signaling pathways relevant for in vivo bone formation based on the ability of hBMSC to form bone in vivo. We employed two previously established hBMSC lines derived from telomerase-immortalized hBMSCs (hBMSC-TERT) that exhibited either ectopic bone forming or non-bone forming phenotype when implanted in vivo into immunodeficient mice. Employing whole transcriptome profiling comparing these two hBMSC lines, we identified the molecular signature and signaling pathways associated with the bone-forming phenotype. Most importantly, our data suggest the convergence of TGFβ- and BMP4-signaling pathways during osteoblastic lineage commitment of hBMSC.

Materials and Methods

Ethics statement. This study did not involve human or animal subjects, therefore ethical approval is not required.

Cell culture. We employed the hMSC-TERT cell line which was created from primary normal human MSC by overexpressing human telomerase reverse transcriptase gene (hTERT). The hMSC-TERT cell lines have been extensively characterized and they exhibited similar cellular responses and molecular phenotype to primary hBMSC. For ease, we will refer to this cell line as ‘hBMSC’ for the remaining part of this manuscript. In the current experiment, we employed two sub-clones of high bone-forming cells (hBMSC+Bone) and low bone-forming cells (hBMSC−Bone) which were derived from early-passage hMSC-TERT cell lines with a population doubling level of (PDL) 77 as well as from late-passage hBMSC-TERT cells (PDL = 233), respectively, as previously described. The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with D-glucose 4500 mg/L, 4 mM L-Glutamine, 110 mg/L Sodium Pyruvate, 10% Fetal Bovine Serum (FBS), 1x penicillin–streptomycin (Pen-strep), and non-essential amino acids (all purchased from Thermo Fisher Scientific, Waltham, MA), at 37 °C in a humidified atmosphere containing 5% CO2.

siRNA-mediated transfection of hMSC. For transfection experiments, hBMSC cells in logarithmic growth phase were reverse-transfected with Silencer Select Pre-designed and Validated SERPINB2-siRNA (25 nM) (Ambion ID: 100116, 10017, and 10018, Cat. No. 4394240) using Lipofectamine 2000 Reagent (25 nM) (Ambion ID: s10016, s10017, and s10018, Cat. No. 4392420, Thermo Fisher Scientific Life Sciences, USA), or NOG-siRNA (25 nM) (Ambion ID: s34108, Cat. No. 4392420) using Lipofectamine 2000 Reagent (Invitrogen), plus serum-free Opti-MEM I medium (Thermo Fisher Scientific, Waltham, MA) as per the manufacturer’s recommendations. On day 3 of transfection, the cells were induced into osteoblast (OS) or adipocyte (AD) media.

In vitro osteoblast differentiation. Cells were grown in standard DMEM growth medium in 6-well plates at 0.3 × 10⁶ cells/ml. When a 70–80% cell confluence was reached, the cells were cultured in DMEM supplemented with an osteoblast induction mixture containing 10% FBS, 1% Pen-strep, 50 µg/mL L-ascorbic acid (Wako Chemicals, Neuss, Germany), 10 mM β-glycerophosphate (Sigma), 10 nM calcitriol (1α,25-dihydroxy vitamin D3; Sigma), and 10 nM dexamethasone (Sigma). The media was replaced 3 times per week.

In vitro adipocyte differentiation. Cells were grown in standard DMEM growth medium in 6-well plates at 0.3 × 10⁶ cells/ml. When a 90–100% cell confluence was reached, the cells were cultured in DMEM supplemented with adipogenic induction mixture containing 10% FBS, 10% Horse Serum (Sigma-Aldrich, St. Louis, MO), 1% Pen-strep, 100 nM dexamethasone, 0.45 mM isobutyl methyl xanthine (Sigma, US), 3 μg/mL insulin (Sigma, US), and 1 μM Rosiglitazone (Novo Nordisk, Bagsvaerd, Denmark). The media used was replaced 3 times per week.

to quantify ALP activity in hBMSC before and after OS differentiation, we used the BioVision ALP activity colorimetric assay kit (Biovision Inc., Milpitas, CA) with some modifications. Cells were cultured in 24-well plates under normal conditions; then, on the day of analysis, wells were rinsed once with PBS and were fixed using 3.7% formaldehyde in 90% ethanol for 30 seconds at room temperature. Subsequently, the fixative was removed, and 50 µL of PNP solution was added to each well and the cells were next incubated for 1 hour in the dark at room temperature. The reaction was subsequently stopped by adding 20 µL stop solution and gently shaking the plate. The OD was then measured at 405 nm.

Osteolmage mineralization assay. The in vitro formed mineralized matrix was quantified using the Osteolmage ™ Mineralization Assay Kit (LONZA, USA, Cat. No. PA-1503). After this, the culture media was removed and the cells were washed once with PBS and then fixed with 70% cold ethanol for 20 minutes. The appropriate amount (as per the manufacturer’s recommendations) of diluted staining reagent was added, and the
plates were incubated in the dark for 30 minutes at room temperature. The cells were then washed and staining quantitation was performed using a fluorescent plate reader (SpectraMax M5 Molecular Devices, Sunnyvale, CA) at 492/520 excitation emission wavelengths.

**Oil red-O staining for lipid droplets.** Mature adipocytes filled with cytoplasmic lipid droplets were visualized by staining with Oil Red-O. After washing with PBS, the cells were fixed in 4% formaldehyde for 10 minutes at room temperature, then rinsed once with 3% isopropanol, and stained for 1 hr at room temperature with filtered Oil Red-O staining solution (prepared by dissolving 0.5 g Oil Red-O powder in 60% isopropanol). To quantify the mature adipocytes that were formed, Oil Red O stain was eluted by adding 100% isopropanol to each well. The color intensity was then measured using Biotek™ Epoch™ Microplate Spectrophotometer (BioTek Instruments Inc., Winooski, VT) spectrophotometer at 510 nm.

**Nile red fluorescence determination and quantification of mature adipocytes.** A stock solution of Nile red (1 mg/ml) in DMSO was prepared and stored at −20 °C protected from light exposure. Staining was performed on fixed cells using 4% paraformaldehyde (Sigma) for 15 minutes. Cultured undifferentiated and differentiated cells were washed once with PBS. The dye was then added directly to the cells (5 μg/ml in PBS), and the cells were incubated for 10 min at RT. Fluorescent signals were measured using the SpectraMax/M5 fluorescence spectrophotometer plate reader (Molecular Devices Co., Sunnyvale, CA) using the bottom well-scan mode where nine readings were taken per well using an excitation level of 485 nm and an emission level of 572 nm.

**Cell proliferation assays.** Cell viability was measured using the alamarBlue assay according to the manufacturer’s recommendations (Thermo Fisher Scientific, Waltham, MA). In brief, 10 μl of alamarBlue substrate was added to cultured cells in 96-well plates and the plates were incubated in the dark at 37 °C for 1 h. The reading was subsequently taken using fluorescent mode (Ex 530 nm/Em 590 nm) using the BioTek™ Synergy II microplate reader (BioTek Inc., Winooski, VT, USA).

**Western blot analysis.** Cells were lysed using RIPA buffer (Thermo Fisher Scientific, Waltham, MA) and soluble proteins were immunoblotted using P-SMAD2 (Cell Signaling Technology, Danvers, MA, Cat no. 9523, diluted 1:500) and anti-β-ACTIN (Sigma-Aldrich, St. Louis, MO, A3854, diluted according to a ratio of 1:10,000). Reactivity was detected with horseradish peroxidase-conjugated secondary antibodies (Santa-Cruz Biotechnology, Inc., Dallas, TX) and Clarity™ western ECL substrate (Bio-Rad) for chemiluminescence using C-Digit Blot Scanner (Li-Cor Bioscience, Lincoln, NE).

**DNA microarray global gene expression profiling.** Total RNA was extracted using PureLink RNA mini isolation kit (by Ambion Life Technologies, Carlsbad, CA, Cat No: 12183018 A) as recommended by the manufacturer. One hundred and fifty nanograms of total RNA were labeled and then hybridized to the Agilent Human SurePrint G3 Human GE 8 × 60 k microarray chip (Agilent Technologies, Santa Clara, CA). All microarray experiments were conducted at the Microarray Core Facility (Stem Cell Unit, King Saud University College of Medicine). Normalization and data analyses were conducted using GeneSpring GX software (Agilent Technologies). Pathway analysis was conducted using the Single Experiment Pathway analysis feature in GeneSpring 12.0 (Agilent Technologies) as previously described. A two fold cutoff with P < 0.02 was used.

**Quantitative real time PCR (qRT-PCR).** Total RNA was extracted using PureLink kit (Ambion Life Technologies, Carlsbad, CA, Cat No: 12183018A) as recommended by the manufacturer. Total RNA was quantified by using the Nanodrop™ spectrophotometer (Nanodrop 2000, Thermo Fisher Scientific, Inc., Waltham, MA). Complementary DNA (cDNA) was synthesized from 1 μg of the RNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosysytem, USA) and Labnet Multigene thermocycler (Labnet International Inc., Edison, NJ) according to the manufacturer’s instructions. Relative levels of mRNA were determined from cDNA using Power SYBR Green PCR kit or the TaqMan Universal master Mix II with noUNG, both from Applied Biosystems (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. Following normalization to the reference gene GAPDH, the quantification of gene expression was carried out by using a comparative Ct method where ΔCT is the difference between the CT values of the target and the reference gene. The primers that were used are listed in supplementary Tables 1.

**Statistical analysis.** All of the results were presented as the mean and standard deviation (SD) of at least 3 independent experiments. A Student’s t-test was used for testing the differences between groups. P-values < 0.05 was considered statistically significant.

**Results**

**Molecular heterogeneity of bone-and non-bone-forming hBMSC clones.** We previously derived two clonal hBMSC lines with bone-forming (hBMSC+ Bone) or non-bone forming (hBMSC− Bone) properties. The clonal lines were derived from the parental hBMSC-TERT cell line). As shown in Fig. 1a, hBMSC− Bone exhibited low osteoblastic (OB) differentiation potential when compared to hBMSC+ Bone as evidenced by decreased ALP activity (Fig. 1a, upper panel) as well as decreased extracellular mineralized matrix formation (Fig. 1a, lower panel). The expression of the osteoblastic lineage gene markers: alkaline phosphatase (ALPL), runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), osteronectin (ON), osteopontin (OPN), bone morphogenetic protein 4 (BMP4), and collagen-1A1 (COL1A1) was also decreased (see Fig. 1b). Similarly, hBMSC− Bone showed low in vitro adipocytic (AD) differentiation potential as evidenced by the decreased formation of mature lipid-filled adipocytes (Fig. 1c,d) as well as the reduced expression of the adipocyte lineage gene markers: adipocyte protein 2 (aP2), lipoprotein lipase (LPL), and peroxisome proliferator-activated receptor...
gamma 2 (PPARγ2) (Fig. 1e). hBMSC \( + \) Bone cells exhibited enhanced differentiation potential into osteoblastic and adipocytic cells versus hBMSC-Bone, which has limited differentiation capacity.

Impaired TGFβ signaling pathway in hBMSC\(^{-}\)Bone. We compared the whole transcriptome using global gene expression profiling of hBMSC \(+\) Bone and hBMSC\(^{-}\)Bone to identify the molecular signature that was predictive of functional divergence. The top ten significantly enriched KEGG pathways in the downregulated genes in hBMSC\(^{-}\)Bone is illustrated as pie chart in Fig. 2a. Interestingly, several TGF\(\beta\)-responsive genes were dysregulated in hBMSC\(^{-}\)Bone compared with hBMSC \(+\) Bone (Fig. 2a) including RUNX2, BMP2, BMP4, SMAD6, SMAD9, TGF\(\beta\)2, TGLN, TPM1, ACTA2, COL1A1, SERPINB2, and NOG, suggesting the suppression of the TGF\(\beta\) signaling pathway in hBMSC\(^{-}\)Bone. Validation of the microarray data using qRT-PCR revealed good concordance between the microarray data and qRT-PCR for a selected panel of TGF\(\beta\) responsive genes including: TAGLN, ACTA2, and SERPINB2 (see Fig. 2b). Our previous data demonstrated inverse correlation between SERPINB2 upregulation and TGF\(\beta\) activation\(^{22}\). Furthermore, Western blot analysis of phosphorylated SMAD2 (p-SMAD2) revealed a marked reduction in p-SMAD2 in hBMSC\(^{-}\)Bone vs hBMSC \(+\) Bone at baseline (Fig. 2c, upper panel), on day 10 during in vitro osteoblastic (Fig. 2c, middle panel), as well as adipocytic (Fig. 2c, lower panel) differentiation. Taken together, those data demonstrated impaired TGF\(\beta\) signaling in the hBMSC\(^{-}\)Bone line.

Exogenous TGF\(\beta1\) promotes osteogenic and adipogenic differentiation of hBMSC\(^{-}\)Bone cells. We subsequently assessed the effect of TGF\(\beta1\) (10 ng/ml) treatment on hBMSC \(+\) Bone cell proliferation and differentiation into osteoblasts and adipocytes. The hBMSC\(^{-}\)Bone cells exhibited no changes in cell proliferation or viability when treated with TGF\(\beta1\) (Fig. 3a); however, TGF\(\beta1\) treatment led to upregulation of a number
ALP activity and the quantification of formed mineralized matrix revealed significant increase in the osteoblastic differentiation of hBMSC−Bone in response to TGFβ1 treatment (Fig. 1c) and was corroborated by the increased gene expression of the osteoblastic markers: ALPL, RUNX2, ON, OSP, and BMP4 (Fig. 3d). Similarly, qualitative and quantitative Nile red staining of mature adipocytes revealed enhanced adipogenesis in response to TGFβ1 treatment (Fig. 3e,f). The data we have generated, therefore, supports a role for TGFB signaling in the regulation of both osteoblast and adipocyte differentiation of hBMSC−Bone cells, where activation of TGFβ signaling in hBMSC−Bone cells using recombinant TGFβ1 protein as able to rescue their osteoblastic differentiation phenotype.

Silencing SERPINB2 promotes osteoblastic and adipocytic differentiation of hBMSC−Bone cells. As shown in Fig. 2a, we observed elevated gene expression levels of SERPINB2 (3.2 FC), a TGFB-responsive gene, in the hBMSC−Bone cells. We have previously reported a negative regulatory role for SERPINB2 in hBMSC differentiation22. Thus, we employed a loss-of-function approach to determine the role of SERPINB2 in hBMSC−Bone biology. The siRNA-mediated depletion of SERPINB2 had no effect on cell viability (Fig. 4a), while it led to significant increase in the expression of TGFβ-responsive genes, such as TAGLN, ACTA2, TPM1, COL1A2, SMAD2, and SMAD4 (Fig. 4a). In addition, SERPINB2-depleted hBMSC−Bone cells exhibited enhanced osteoblastic differentiation potential as demonstrated by increased qualitative and quantitative mineralized matrix formation (Fig. 4c), and associated with upregulation of the osteoblastic gene markers: ALPL, RUNX2, OCN, OPN, BMP4, and COL1A1 (Fig. 4d). Similarly, SERPINB2 depletion during adipogenesis led enhanced adipocytic differentiation characterized by the increase in the number of Nile red positive mature adipocytes (Fig. 4c) as well as the upregulation of adipocyte gene markers: AP2, LPL, and PPARG2 (Fig. 4f). Therefore, activation of TGFβ signaling in hBMSC−Bone cells using siRNA-mediated knockdown of SERPINB2 partially restored their osteoblastic differentiation potential.

Gene expression profiling of SERPINB2-depleted hBMSC−Bone cells. Given the observed effects of SERPINB2-depletion on rescuing osteoblastic and adipocytic differentiation of hBMSC−Bone cells, we sought to determine the underlying molecular mechanisms linking SERPINB2 to osteoblastic and adipocytic differentiation.
in hBMSC−Bone cells. Hence, we performed global gene expression profiling on SERPINB2-depleted hBMSC−Bone compared to scrambled-transfected control cells. Hierarchical clustering based on differentially expressed transcripts revealed distinct clustering of the two groups (Fig. 5a). We identified 480 up-regulated and 423 down-regulated genes in SERPINB2-depleted hBMSC−Bone cells (2.0 FC, p < 0.05; Supplementary Table 2). Pathway analysis was performed on the differentially expressed mRNA transcripts revealing significant enrichment in several signaling pathways including focal adhesion, TGFβ signaling, adipogenesis, matrix metalloproteinases, MAPK, and osteoclast signaling (Fig. 5b). Good concordance was observed between the microarray data and qRT-PCR validation of the regulation of a selected number of differentially expressed genes (Fig. 5c). Therefore, our global transcriptome analysis revealed significant restoration of TGFβ signaling pathway in SERPINB2-depleted hBMSC−Bone cells.

**NOG-depleted hBMSC−Bone cells exhibited enhanced osteoblastic and adipocytic differentiation.** BMP is a signaling pathway that exhibit cross-talk with TGFβ signaling during osteoblastic and adipocytic differentiation of hBMSCs 23,24. Interestingly, gene expression profiling (Fig. 2a) revealed a marked upregulation
of NOG expression (12.4 FC) in hBMSC−Bone cells. To determine the biological relevance of this observation, hBMSC−Bone were transfected with NOG siRNA and were exposed to osteoblastic and adipocytic differentiation induction media. The siRNA-mediated silencing of NOG had no significant effects on cell viability (Fig. 6a), however it led to a significant increase in the expression of several TGFβ responsive genes, including TAGLN, ACTA2, TPM1, COL1A2, SMAD2 and SMAD4 (Fig. 6b). Interestingly, we also observed downregulation of SERPINB2 in NOG-depleted cells. Concordant with TGFβ activation, NOG−deficient hBMSC−Bone cells exhibited enhanced osteoblast differentiation as shown by a significant increase in mineralized matrix formation and increased ALP activity (Fig. 6c) as well as an increase in the expression of a number of osteoblastic gene markers: ALPL, RUNX2, OCN, and COL1A1 (Fig. 6d). Similarly, NOG−deficient hBMSC−Bone cells exhibited enhanced adipocytic differentiation shown by the increased number of lipid-filled mature adipocytes (Fig. 6e) and up-regulated expression of AN, LPL and PPARg2 AD gene markers (Fig. 6f). The activation of BMP signaling via siRNA-mediated knockdown of NOG partially restored the differentiation phenotype of hBMSC−Bone cells.
NOG suppresses osteoblastic and adipocytic differentiation of hBMSC−Bone cells. To confirm the role of NOG in regulating hBMSC differentiation, recombinant NOG (10 ng/ml) was added to the osteoblastic and adipocytic differentiation induction media of hBMSC−Bone cells. NOG-treated hBMSC−Bone cells did not seem to exhibit any changes in cell proliferation (Fig. 7a). Moreover, gene expression analysis revealed downregulation of ACTA2 and TPM1 and upregulation of SERPNB2 expression levels in NOG-treated hBMSC−Bone cells (Fig. 7b). Moreover, NOG treatment diminished the osteoblastic differentiation of hBMSC−Bone cells as demonstrated by an overall reduction in mineralized matrix formation (Fig. 7c), as well as the decreased expression of ALPL, RUNX2 and ON osteoblastic gene markers (Fig. 7d). Furthermore, NOG-treated hBMSC−Bone cells exhibited diminished adipocytic differentiation as evidenced by the reduced number of lipid-filled mature adipocytes (Fig. 7e) and the downregulation of AP2, AN, LPL and PPARg2 adipocytic markers (Fig. 7f). Therefore and in support of the NOG loss-of-function data presented in Fig. 6, recombinant NOG impaired ex vivo osteoblastic and adipocytic differentiation of hBMSC−Bone cells.

BMP4 promotes osteogenic and adipogenic differentiation of hBMSC−Bone cells. BMP4 is one of the BMPs produced by MSCs and plays a role during their osteoblastic differentiation.25 We observed a significant downregulation of BMP4 gene expression in hBMSC−Bone cells (−9.2 FC) (Fig. 2a). Since NOG antagonizes BMP signaling, we assessed the effects of exogenous BMP4 (50 ng/ml) treatment on hBMSC−Bone cells. BMP4 treatment up-regulated TGALN, TPM1, and COL1A2 in hBMSC−Bone cells (Fig. 8a). BMP4 treatment also exhibited enhanced ALP activity and mineralized matrix formation (Fig. 8c). Concordantly, gene expression analysis showed upregulated ALPL, OCN, ON, and COL1A1 osteoblastic genes (Fig. 8d). Similarly, BMP4-treated hBMSC−Bone cells also exhibited enhanced adipocytic differentiation marked by an increased number of lipid-filled mature adipocytes (Fig. 8e) and the increased expression of LPL and CEBPA adipocytic gene markers (Fig. 8f). Therefore, activation of BMP signaling using exogenous BMP4 was able to partially restore the differentiation phenotype of hBMSC−Bone cells.

Discussion
Delineating signaling pathways regulating hBMSC osteoblastic and adipocytic lineage commitment and differentiation is an area of active investigation. Our recent research highlighted the existence of functional heterogeneity in cultured hBMSCs and the presence of progenitors at different stages of lineage commitment with different functional capacities. Herein we investigated hBMSC−Bone cells, which can differentiate readily into osteoblastic
and adipocytic cells versus hBMSC-Bone, which has limited differentiation capacity. Our data revealed TGFβ3 signaling as a major molecular pathway associated with differentiation responsiveness of hBMSCs. Interestingly, the loss of this signaling pathway in hBMSC Bone was reversible, suggesting an epigenetic rather than genetic aberration in hBMSC Bone cells and may be related to cellular heterogeneity of cultured hBMSC.

To gain more in depth insight into the signaling networks associated with the bone and none-bone forming phenotype, we performed global transcriptome profile for both cell types and identified a number of altered signaling pathways. Our data revealed hBMSC Bone exhibited significant downregulation of several TGFβ3 responsive genes including TAGLN, TMP1, ACTA2, TGFβ2, SMAD6, SMAD9, BMP2, and BMP4 genes as well as the upregulation of SERPINB2 and NOG. Concordantly, hBMSC Bone exhibited low basal phosphorylation of the SMAD2 protein, even under induction conditions, suggesting diminished TGFβ3 and BMP signaling in hBMSC Bone cells. Activating either TGFβ3 or BMP signaling in hBMSC Bone cells was able to partially rescue their differentiation phenotype, thereby implying epigenetic rather than permanent differentiation impairment in those cells.

Our data further unraveled a complex interaction between TGFβ and BMP signaling during hBMSC differentiation (Fig. 8g). Exogenous TGFβ3I stimulus exhibited similar effects to those inflicted by SERPINB2 knockdown on restoring the osteogenic and adipogenic differentiation of hBMSC Bone cells, which would be concordant with
our recent finding of bidirectional regulation between SERPINB2 and TGFβ signaling. Plasminogen activator inhibitor-2 (also known as PAI-2), is a serine protease inhibitor of the serpin superfamily, which serves as a coagulation factor by inactivating the urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It is expressed in most cells, especially in macrophages and monocytes, but exists in undetectable quantities in the blood. It is highly expressed during pregnancy, infection, inflammation, and other pathophysiological conditions. Increasing accumulated information on the biochemistry, biology, and clinical aspects of SERPINB2 has revealed its involvement in various intracellular and extracellular physiological and pathological processes. It is involved in maintaining homeostasis during stress, damage, or inflammation. It has been recently reported that SERPINB2 expression is necessary for in vitro collagen remodeling in stromal cells. SERPINB2 in stromal cells is a necessary component during extracellular matrix remodeling for fibroblast-contracted collagen 1 matrix

Figure 7. Exogenous NOG suppresses osteoblastic and adipocytic differentiation of hBMSC Bone cells. (a) Quantification of cell viability measured on days 1, 4, and 6 for hBMSC Bone cells in the presence or absence of recombinant NOG (50 ng/ml). (b) qRT-PCR performed for TPM1, SMAD2 and SERPINB2 TGFβ responsive genes in hBMSC Bone cells in the presence or absence of recombinant NOG (10 ng/ml). The expression of each target gene was normalized to GAPDH. Data are presented as mean ± SD from three independent experiments, *p < 0.005. (c) Osteolmage staining (20 × magnification) of hBMSC Bone cells which were induced into the osteoblast in the presence or absence of recombinant NOG. The lower panel shows Alizarin Red S staining. The quantification of mineralized matrix formation for vehicle or recombinant NOG-treated hBMSC Bone cells is shown (right panel). Data are presented as relative mean mineralization ± SD from three independent experiments, n = 9; *p < 0.0005. (d) qRT-PCR quantification of ALPL, RUNX2, OCN, and COL1A1 osteogenic markers in hBMSC Bone cells in the presence or absence of recombinant NOG (10 ng/ml) under osteogenic induction conditions. The expression of each target gene was normalized to GAPDH. Data are presented as the means ± SD from three independent experiments, n = 9; **p < 0.0005, ***p < 0.0005. (e) hBMSC Bone cells were differentiated into adipocytes for 7 days under the indicated experimental conditions. Upper panel shows fluorescence Nile red staining of mature oil filled adipocytes (20 × magnification), whilst the lower panel shows Oil red O staining for adipocytes (20 × magnification). The lower panel shows the relative quantification of Nile red staining of mature oil-filled adipocytes. (f) qRT-PCR quantification for AP2, AN, LPL and PPARγ2 adipocytic markers. The expression of each target gene was normalized to GAPDH. Data are presented as mean ± SD from three independent experiments, n = 9; ***p < 0.0005.
Moreover, SERPINB2 was one of the highly regulated genes in hBMSC−Bone, suggesting that it most likely plays a role in the blocking of TGF-β-mediated hBMSC differentiation.

On the other hand, the silencing of NOG in hBMSC−Bone has similar effects to those inflicted by an exogenous BMP4 stimulus on promoting osteoblast and adipocytes lineage commitment and differentiation. This suggests that there may well be a plausible convergence of the TGFβ and BMP signaling in regulating hBMSC differentiation. BMPs are involved in the TGFβ superfamily, which is known to participate in the regulation of stem cell proliferation and differentiation. Specifically, BMPs are involved in the regulation of osteogenesis and in *in vivo* bone formation. During development, the disruption of BMPs is associated with skeletal and extra-skeletal abnormalities. Furthermore, it has been shown that BMPs play an important role in bone healing due to their ability to stimulate the osteoblastic differentiation of hBMSC. NOG is a BMP extracellular antagonist that negatively regulates BMP signaling through binding to their receptors leading to impaired osteogenesis and
bone formation. In our system, exogenous NOG lead to the suppression of BMP signaling, thereby causing impaired in vitro bone formation. In addition, overexpression of NOG in the skeletal system leads to reduced bone formation and osteopenia. It has been reported that inhibition of NOG either using NOG-neutralizing antibodies or siRNA led to enhanced BMP-dependent osteogenesis of hSBMC in vitro and in vivo. Interestingly, our data revealed the existence of reciprocal relationship between SERPINB2 and NOG. Therefore, we propose a schematic model illustrating dual signaling network comprising TGFβ-mediated SERPINB and NOG-dependent BMP4 signaling that regulate osteoblastic and adipocytic differentiation of hBMSC-Bone. Our model suggests novel reciprocal relationship between SERPINB2 and NOG.

Our study has some limitations. We have employed human immortalized hBMSC lines in order to dissect the interaction between TGFβ and BMP signaling and in order to avoid confounders of age, gender, in vitro replicative senescence phenotype associated with use of primary hBMSC. Also, our studies were based on in vitro mechanistic approaches. Future studies examining changes in TGFβ and BMP signaling in cohorts of human subjects of different age and gender as well as its relationship to in vivo bone phenotype are needed.

Our study suggests that targeting of the SERPINB/TGFβ and NOG/BMP axes is a plausible future strategy for enhancing in vitro osteoblast commitment and differentiation of hBMSC prior to their use in clinical transplantation. Also, the relevance of using small molecules that regulate these signaling pathways in the treatment of patients with impaired bone formation e.g. age-related osteoporosis, remain to be examined in preclinical and clinical studies.

Data Availability
Raw data will be provided upon acceptance of the manuscript.

References
1. Bianco, P., Robey, P. G. & Simmons, P. J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2(4), 313–9 (2008).
2. Abdallah, B. M. & Kassem, M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther 15(2), 109–16 (2008).
3. Larsen, K. H. et al. Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone-forming capacity. J Bone Miner Res 25(4), 796–808 (2010).
4. Elsafadi, M. et al. Characterization of Cellular and Molecular Heterogeneity of Bone Marrow Stromal Cells. Stem Cells Int 2016, 9378081 (2016).
5. Zahir, W. et al. An update of human mesenchymal stem cell biology and their clinical uses. Arch Toxicol 88(5), 1069–82 (2014).
6. Kassem, M. & Marie, P. J. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 10(2), 191–7 (2011).
7. Watson, L., Elliott, S. J. & Coleman, C. M. From isolation to implantation: a concise review of mesenchymal stem cell therapy in bone fracture repair. Stem Cell Res Ther 5(2), 51 (2014).
8. Ren, G. et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med 1(1), 51–8 (2012).
9. Kratchmarova, I. et al. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308(5727), 1472–7 (2005).
10. Kristensen, L. P. et al. Temporal profiling and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem cells. Mol Cell Proteomics 11(10), 989–1007 (2012).
11. Ali, D. et al. Multiple intracellular signaling pathways orchestrate adipocytic differentiation of human bone marrow stromal stem cells. Biosci Rep, 38(1) (2018).
12. Abdallah, B. M. et al. CRMP4 Inhibits Bone Formation by Negatively Regulating BMP and RhoA Signaling. J Bone Miner Res 32(5), 913–926 (2017).
13. Jafari, A. et al. Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis. Stem Cell Reports 8(2), 373–386 (2017).
14. Abdallah, B. M., Ditzel, N. & Kassem, M. Assessment of bone formation capacity using in vivo transplantation assay procedure and tissue analysis. Methods Mol Biol 455, 89–100 (2008).
15. Simonson, J. L. et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 20(6), 592–6 (2002).
16. Abdallah, B. M. et al. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem Biophys Res Comm 326(3), 527–38 (2005).
17. Al-Nabheen, M. et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev 9(1), 32–43 (2013).
18. Hildegard, A. et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302(Pt 2), 527–34 (1994).
19. Serra, R. & Chang, C. TGF-beta signaling in human skeletal and patterning disorders. Birth Defects Res C Embryo Today 69(4), 333–51 (2003).
20. Gregory, C. A. et al. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem 329(1), 77–84 (2004).
21. Ali, D. et al. Romidepsin Promotes Osteogenic and Adipocytic Differentiation of Human Mesenchymal Stem Cells through Inhibition of Histoneacetylase Activity. Stem Cells Int 2018, 2379546 (2018).
22. Elsafadi, M. et al. SERPINB2 is a novel TGF-beta-responsive lineage fate determinant of human bone marrow stromal cells. Sci Rep 7(1), 10797 (2017).
23. Wu, M., Chen, G. & Li, Y. P. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res 4, 16009 (2016).
24. Chen, Q. et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ 23(7), 1128–39 (2016).
25. Yamaguchi, A., Komori, T. & Suda, T. Regulation of osteoblast differentiation mediated by bone morphogenic proteins, hedgehogs, and Cbfa1. Endocr Rev 21(4), 393–411 (2000).
26. Hisel, H. H. et al. The serine protease inhibitor serpinB2 binds and stabilizes p21 in senescent cells. J Cell Sci 130(19), 3272–3281 (2017).
27. Lee, J. et al. Forty years later and the role of plasminogen activator inhibitor type 2/SERPINC1 is still an enigma. Semin Thromb Hemost 37(4), 395–407 (2011).
28. Kruthof, E. K., Baker, M. S. & Bunn, C. L. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86(11), 4007–24 (1995).
29. Harris, N. L. E. et al. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene 36(30), 4288–4298 (2017).
30. Attisano, L. & Wrana, J. L. Signal transduction by the TGF-beta superfamily. Science 296(5573), 1646–7 (2002).
31. Deng, Z. L. et al. Regulation of osteogenic differentiation during skeletal development. Front Biosci 13, 2001–21 (2008).
32. Lui, H. H. et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 25(9), 665–77 (2007).
33. Wozney, J. M. & Rosen, V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 346, 26–37 (1998).
34. Reddi, A. H. Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am 83-A Suppl 1(Pt 1), S1–6 (2001).
35. Rosen, V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 1068, 19–25 (2006).
36. Capdevila, J. & Johnson, R. L. Endogenous and ectopic expression of noggin suggests a conserved mechanism for regulation of BMP function during limb and somite patterning. Dev Biol 197(2), 205–17 (1998).
37. Walsh, D. W. et al. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 20(5), 244–56 (2010).
38. Zakin, L. & De Robertis, E. M. Extracellular regulation of BMP signaling. Curr Biol 20(3), R89–92 (2010).
39. Devlin, R. D. et al. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144(5), 1972–8 (2003).
40. Wu, X. B. et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 112(6), 924–34 (2003).
41. Fan, J. et al. Enhanced osteogenesis of adipose derived stem cells with Noggin suppression and delivery of BMP-2. PLoS One 8(8), e72474 (2013).

Acknowledgements
This work was funded by National Plan for science, Technology and Innovation (MAARIFAH), King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia, Award Number (BIO1308-02).

Author Contributions
M.E. performed experiments and wrote manuscript; T.S., S.A., M.M. performed experiments; A.M., A.A., M.A., M.K. conceived the study; N.M.A. conceived study, obtained funding, edited and approved final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-41543-0.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.